Table 5.
Japanese reports of the effect of muscle mass evaluated by CT on clinical outcome for hepatocellular carcinoma patients.
| Author | Year | No. of cases | HCC therapy | Evaluation method for muscle mass | Prevalence of muscle mass loss | Outcome |
|---|---|---|---|---|---|---|
| Our study | 2017 | 182 | RFA | CT (L3, PMI) | 49.5% | P<0.05 (OS) |
| Hiraoka, et al. [31] | 2016 | 93 | Sorafenib | CT (L3, PMI) | 21.5% | P=0.042 (OS) |
| Kamachi, et al. [18] | 2016 | 92 | Surgery or RFA | CT (L3, SMI) | 66.3% | P<0.05 (RFS) |
| Iritani, et al. [32] | 2015 | 217 | Any | CT (L3, SMI) | 11.1% | P<0.05 (OS) |
| Fujiwara, et al. [15] | 2015 | 1257 | RFA or TACE | CT (L3, SMI) | 11.1% | P<0.05 (OS) |
| Hamaguchi, et al. [20] | 2014 | 200 | LT | CT (L3, PMI) | 44.0% | P<0.05 (OS) |
| Ito, et al. [14] | 2014 | 190 | Surgery | CT (L3, SMI) | 40.5% | P<0.05 (OS) |
| Harimoto, et al. [17] | 2013 | 186 | Surgery | CT (L3, SMI) | 40.3% | P<0.05 (OS) |
CT; computed tomography, RFA; radiofrequency ablation, L3; the third lumber, PMI; psoas muscle index, SMI; skeletal muscle index, TACE; transcatheter arterial chemoembolization, LT; liver transplantation, OS; overall survival, RFS; recurrence free survival.